Study guide

8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis

Key Takeaways Explain This Topic AI

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, formerly NAFLD) requires hepatic steatosis plus at least one cardiometabolic risk factor; risk stratification utilizes the non-invasive FIB-4 Index (Age, AST, ALT, Platelets) where FIB-4 <1.30 (<2.0 in age ≥65) indicates low risk for advanced fibrosis, while >2.67 mandates hepatology referral for advanced fibrosis/cirrhosis.

In viral hepatitis serology: Hepatitis A acute infection is diagnosed by Anti-HAV IgM; Hepatitis B chronic infection is defined by persistent HBsAg >6 months, while Anti-HBs alone indicates vaccine immunity and Anti-HBs + Anti-HBc Total indicates resolved natural infection; universal one-time Hepatitis C screening (Anti-HCV with reflex HCV RNA PCR) is recommended for all adults aged 18–79.

Alcohol-associated liver disease classically exhibits an AST-to-ALT ratio ≥ 2:1 (with AST typically <300–500 U/L); in acute alcoholic hepatitis, a Maddrey's Discriminant Function (MDF) score ≥ 32 indicates severe disease with high short-term mortality benefiting from oral prednisolone.

In cirrhosis with ascites, diagnostic paracentesis determines the Serum-Ascites Albumin Gradient (SAAG); a SAAG ≥ 1.1 g/dL confirms portal hypertension, managed by dietary sodium restriction (<2,000 mg/day) and dual diuretics (Spironolactone and Furosemide in a 100:40 mg ratio); Spontaneous Bacterial Peritonitis (SBP) is diagnosed by an ascitic fluid absolute neutrophil count (PMN) ≥ 250 cells/mm³, requiring immediate IV ceftriaxone and IV albumin.

Right Upper Quadrant (RUQ) ultrasound is the initial imaging of choice for suspected biliary tract disease; acute cholecystitis presents with sustained RUQ pain, fever, leukocytosis, and a positive Murphy's sign, with HIDA cholescintigraphy serving as the most sensitive confirmatory test if ultrasound is equivocal.

Last updated: August 2026

Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis

Hepatobiliary pathology encompasses a vast spectrum of acute and chronic metabolic, infectious, toxic, and obstructive conditions. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification demands precision in interpreting liver chemistry panels, mastering viral hepatitis serologies, utilizing non-invasive fibrosis scoring tools, managing end-stage liver disease (ESLD) complications, and executing urgent decision-making for acute biliary emergencies.

  • 1. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD / MASH)
  • Updated Multisociety Nomenclature (2023 Consensus)

In 2023, the international hepatology societies (AASLD, EASL, ALEH) updated the nomenclature to replace Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to eliminate stigmatizing language and provide affirmative cardiometabolic diagnostic criteria. +-----------------------------------------------------------------------------+

  • | MASLD / MASH PATHOPHYSIOLOGICAL SPECTRUM |
  • | |
  • | MASLD (Steatotic Liver Disease) |
  • | - Hepatic steatosis (>= 5% hepatocytes on histology or imaging) |
  • | - PLUS at least ONE of 5 Cardiometabolic Risk Factors: |
  • | 1. BMI >= 25 kg/m2 (>= 23 in Asian populations) or Waist Circ >94/80cm |
  • | 2. Fasting Glucose >= 100 mg/dL, 2-hr OGTT >= 140, or Type 2 Diabetes |
  • | 3. Blood Pressure >= 130/85 mmHg or on antihypertensive therapy |
  • | 4. Plasma Triglycerides >= 150 mg/dL or on lipid-lowering therapy |
  • | 5. Plasma HDL-C < 40 mg/dL (men) or < 50 mg/dL (women) |
  • | | |
  • | v |
  • | MASH (Metabolic Dysfunction-Associated Steatohepatitis) |
  • | - Steatosis PLUS hepatocyte ballooning injury and lobular inflammation |
  • | | |
  • | v |
  • | PROGRESSIVE FIBROSIS (Stages F0 to F4) -> CIRRHOSIS -> HEPATOCELLULAR CA |
  • +-----------------------------------------------------------------------------+
  • Primary Care Risk Stratification: The FIB-4 Algorithm

The primary care provider must distinguish simple steatosis (low risk) from progressive steatohepatitis with advanced bridging fibrosis (F3) or cirrhosis (F4). The Fibrosis-4 (FIB-4) Index is the guideline-endorsed first-line non-invasive screening tool: FIB-4 Index Formula:

FIB-4 = (Age [years] × AST [U/L]) / (Platelet Count [10^9/L] × √ALT [U/L]) +-----------------------------------------------------------------------------+

  • | FIB-4 CLINICAL DECISION PATHWAY |
  • | |
  • | [PATIENT WITH MASLD] |
  • | | |
  • | v |
  • | [CALCULATE FIB-4 INDEX] |
  • | | |
  • | +-----------------------------+-----------------------------+ |
  • | | | |
  • | v v |
  • | [LOW RISK: FIB-4 < 1.30] [HIGH RISK: > 2.67]|
  • | (< 2.0 in age >= 65) - Advanced Fibrosis|
  • | - Advanced fibrosis excluded (>90% NPV) or Cirrhosis highly|
  • | - Primary care lifestyle management likely (>80% PPV)|
  • | - Repeat FIB-4 in 2 to 3 years - Immediate HEPATOLOGY|
  • | referral for care|
  • | | |
  • | v |
  • | [INDETERMINATE: FIB-4 1.30 - 2.67] |
  • | - Second-Line Testing: VIBRATION-CONTROLLED |
  • | TRANSIENT ELASTOGRAPHY (FibroScan / VCTE) |
  • | - Liver Stiffness < 8.0 kPa -> Low risk (PCP) |
  • | - Liver Stiffness >= 8.0 kPa -> Refer to Hepatology |
  • +-----------------------------------------------------------------------------+
  • Evidence-Based Management of MASLD / MASH

Lifestyle & Weight Loss: 7% to 10% total body weight reduction achieves histological resolution of steatohepatitis and stabilizes or reverses hepatic fibrosis. Prescribe a Mediterranean diet and ≥ 150 min/week of moderate-intensity aerobic exercise.

Cardiometabolic Pharmacotherapy:

GLP-1 Receptor Agonists (e.g., Semaglutide, Liraglutide): Preferred for patients with concurrent Type 2 Diabetes or obesity; promotes weight loss and reduces steatohepatitis.

Pioglitazone (30–45 mg daily): Improves liver histology in biopsy-proven MASH with or without diabetes (caution: fluid retention, heart failure, weight gain).

Resmetirom (THR-beta agonist): First FDA-approved targeted agent for non-cirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3).

Statin Therapy: Statins are safe and indicated in MASLD/MASH to reduce cardiovascular morbidity (the #1 cause of death in MASLD patients!). Statins are only contraindicated in acute decompensated liver failure.

2. Viral Hepatitis: Serology, Diagnostics & Management +-----------------------------------------------------------------------------+

  • | HEPATITIS B SEROLOGY MASTER INTERPRETATION |
  • | |
  • | SEROLOGIC MARKER CLINICAL MEANING & SIGNIFICANCE |
  • | ----------------------------------------------------------------------- |
  • | HBsAg (Surface Ag) Indicates ACTIVE infection (acute or chronic). |
  • | Persisting > 6 months defines CHRONIC HBV. |
  • | |
  • | Anti-HBs (Surface Ab) Indicates IMMUNITY (from vaccine or cured natural).|
  • | Neutralizing protective antibody (> 10 mIU/mL). |
  • | |
  • | Anti-HBc IgM (Core Ab) Indicates ACUTE infection (< 6 months). Sole |
  • | marker positive during the "WINDOW PERIOD". |
  • | |
  • | Anti-HBc Total / IgG Indicates NATURAL EXPOSURE (past cured or chronic).|
  • | NEVER positive from vaccination alone! |
  • | |
  • | HBeAg (Envelope Ag) Indicates HIGH VIRAL REPLICATION & INFECTIVITY. |
  • | Anti-HBe (Envelope Ab) Indicates SEROCONVERSION (lower replication). |
  • | HBV DNA (PCR) Quantifies active viral load; guides antivirals. |
  • +-----------------------------------------------------------------------------+
  • Definitive HBV Serologic Diagnostic Profiles
  • Clinical Diagnostic State HBsAg Anti-HBs Anti-HBc IgM Anti-HBc Total HBeAg / HBV DNA
  • Susceptible (Never Exposed/Vaccinated) Negative Negative Negative Negative Negative
  • Vaccine-Induced Immunity Negative POSITIVE Negative Negative Negative
  • Natural Immunity (Resolved Past Infection) Negative POSITIVE Negative POSITIVE Negative
  • Acute Hepatitis B Infection POSITIVE Negative POSITIVE POSITIVE POSITIVE (High)
  • "Window Period" (Early Recovery) Negative Negative POSITIVE POSITIVE Low / Undetectable
  • Chronic Hepatitis B (Active / Inactive) POSITIVE Negative Negative POSITIVE Positive (Variable)

Overview of Hepatitis A, C, D, and E +-----------------------------------------------------------------------------+

  • | VIRAL HEPATITIS COMPARATIVE MATRIX |
  • | |
  • | VIRUS TRANSMISSION DIAGNOSTIC TEST CHRONICITY MANAGEMENT |
  • | ----------------------------------------------------------------------- |
  • | HAV Fecal-oral Acute: Anti-HAV IgM NO Supportive. |
  • | (food/water) Immune: Anti-HAV IgG (0%) Vaccine PEP |
  • | within 14 d. |
  • | |
  • | HBV Parenteral, HBsAg, Anti-HBc IgM, YES Entecavir or |
  • | Sexual, Perinatal HBV DNA PCR (5-10% adult Tenofovir if|
  • | >90% infant) active. |
  • | |
  • | HCV Parenteral Screen: Anti-HCV Ab YES Direct-Acting|
  • | (IV drug use, Confirmatory: HCV RNA (75-85%) Antivirals |
  • | transfusions) PCR (Quantitative) (DAAs, 8-12w)|
  • | >95% Cure! |
  • | |
  • | HDV Parenteral, Anti-HDV Ab, HDV RNA YES Requires HBV |
  • | Sexual (Requires HBsAg coat!) (Severe!) coat (HBsAg).|
  • | |
  • | HEV Fecal-oral Anti-HEV IgM, HEV RNA Rare (except Supportive. |
  • | (water, swine) transplant) High fatal in|
  • | pregnancy! |
  • +-----------------------------------------------------------------------------+

Note

Universal Hepatitis C Screening Mandate (USPSTF & CDC): All adults aged 18 to 79 years must receive a universal one-time screening for Hepatitis C virus using an Anti-HCV antibody test with reflex quantitative HCV RNA PCR . A positive antibody with positive HCV RNA confirms active viremia requiring 8 to 12 weeks of pangenotypic Direct-Acting Antiviral (DAA) therapy (e.g., Sofosbuvir-Velpatasvir or Glecaprevir-Pibrentasvir), achieving Sustained Virologic Response (SVR12 = microbiological cure) in > 95% to 98% of patients.

  • 3. Alcohol-Associated Liver Disease & Acute Alcoholic Hepatitis
  • Pathophysiological Spectrum & Laboratory Hallmarks

Chronic excessive alcohol consumption (> 30 g/day in men, > 20 g/day in women) leads to steatosis, alcoholic steatohepatitis, progressive perivenular fibrosis, and micronodular cirrhosis. +-----------------------------------------------------------------------------+

  • | ALCOHOL-ASSOCIATED HEPATITIS LAB PATTERN |
  • | |
  • | * AST to ALT Ratio >= 2:1 (Highly characteristic board hallmark!) |
  • | * AST and ALT levels are typically MODERATE (< 300 - 500 U/L) |
  • | (Transaminases > 1,000 U/L suggest viral, acetaminophen, or ischemic nec)|
  • | * Mechanism of AST > ALT: Pyridoxal-5'-phosphate (Vitamin B6) deficiency |
  • | depletes ALT synthesis; alcohol causes direct mitochondrial AST release.|
  • | * Markedly elevated Gamma-Glutamyl Transferase (GGT) |
  • | * Macrocytosis (MCV > 100 fL) independent of B12/folate |
  • | * Hyperbilirubinemia, elevated INR/PT, and leukocytosis (neutrophilia) |
  • +-----------------------------------------------------------------------------+
  • Severe Acute Alcoholic Hepatitis & Maddrey's Discriminant Function

Acute alcoholic hepatitis presents with acute-onset jaundice, fever, tender hepatomegaly, anorexia, ascites, and leukocytosis in a patient with heavy alcohol intake.

Maddrey's Discriminant Function (MDF) Calculation: MDF = 4.6 × [PT_patient - PT_control] (seconds) + Total Bilirubin (mg/dL)

Clinical Decision: An MDF ≥ 32 indicates severe alcoholic hepatitis with an estimated 30-day mortality of 30% to 50%. In the absence of active GI bleeding or systemic infection, initiate Prednisolone 40 mg daily for 28 days , followed by a taper (evaluated at Day 7 via the Lille Model to assess steroid responsiveness).

4. Cirrhosis & Complications of End-Stage Liver Disease (ESLD)

Cirrhosis is the irreversible, diffuse architectural distortion of the liver characterized by hepatic parenchymal necrosis, regenerative nodule formation, and dense bridging collagen deposition. It leads to portal hypertension (hepatic venous pressure gradient HVPG > 5 mmHg) and progressive liver synthetic failure. +-----------------------------------------------------------------------------+

  • | PHYSICAL STIGMAS OF CIRRHOSIS |
  • | |
  • | [PORTAL HYPERTENSION] [HYPERESTROGENISM / SYNTHETIC FAILURE] |
  • | * Splenomegaly (leads to * Spider Angiomas (upper trunk/face) |
  • | thrombocytopenia < 150k) * Palmar Erythema (thenar/hypothenar) |
  • | * Ascites & Caput Medusae * Gynecomastia & Testicular Atrophy |
  • | * Gastroesophageal Varices * Loss of axillary / pubic body hair |
  • | * Internal Hemorrhoids * Terry's Nails (white proximal nailbed)|
  • | * Dupuytren's Contracture |
  • | [HEPATIC ENCEPHALOPATHY] * Coagulopathy (Elevated INR / PT) |
  • | * Asterixis ("Flapping Tremor") * Hypoalbuminemia & Peripheral Edema |
  • | * Inverted Sleep-Wake Cycle * Jaundice & Scleral Icterus |
  • +-----------------------------------------------------------------------------+

Major Complications of Cirrhosis & Clinical Management +-----------------------------------------------------------------------------+

  • | CIRRHOSIS COMPLICATIONS & MANAGEMENT |
  • | |
  • | 1. ASCITES & SAAG CALCULATION |
  • | - Diagnostic Paracentesis: Calculate Serum-Ascites Albumin Gradient: |
  • | SAAG = Serum Albumin - Ascitic Fluid Albumin |
  • | * SAAG >= 1.1 g/dL: PORTAL HYPERTENSION (Cirrhosis, HF, Budd-Chiari) |
  • | * SAAG < 1.1 g/dL: NON-PORTAL HYPERTENSION (Peritoneal Carcinomatosis|
  • | Peritoneal TB, Pancreatitis, Nephrotic Syndrome) |
  • | - Medical Management: Dietary Sodium Restriction (< 2,000 mg/day). |
  • | - Dual Diuretics: SPIRONOLACTONE + FUROSEMIDE in a 100 mg : 40 mg |
  • | ratio (maintains normokalemia; titrate up to 400 mg : 160 mg). |
  • | - Large-Volume Paracentesis (> 5 L drained): Administer 25% IV ALBUMIN |
  • | at 6 to 8 grams per liter of fluid removed to prevent PICD. |
  • | |
  • | 2. SPONTANEOUS BACTERIAL PERITONITIS (SBP) |
  • | - Definition: Ascitic fluid infection without a surgical source. |
  • | - Diagnostic Criteria: Ascitic Absolute Neutrophil Count (PMN) >= 250 |
  • | cells/mm3 (PMN = Total Ascitic WBC x % Neutrophils). |
  • | - Empiric Treatment: IV CEFTRIAXONE (2g IV Q24H) x 5-7 days PLUS |
  • | IV ALBUMIN (1.5 g/kg within 6 hrs of dx, then 1.0 g/kg on Day 3) to |
  • | prevent Hepatorenal Syndrome and reduce mortality. |
  • | - Secondary Prophylaxis: Daily oral Ciprofloxacin or TMP-SMX for life. |
  • | |
  • | 3. GASTROESOPHAGEAL VARICES |
  • | - Primary Prophylaxis (medium/large varices or red wale marks): |
  • | NON-SELECTIVE BETA-BLOCKERS (Nadolol, Propranolol, or CARVEDILOL) |
  • | to reduce portal inflow; OR Endoscopic Variceal Ligation (EVL). |
  • | - Acute Variceal Bleed: IV Octreotide bolus + infusion, IV Ceftriaxone |
  • | prophylaxis x 7 days, restrictive blood transfusion (target Hb 7-8), |
  • | urgent EGD banding within 12 hours. |
  • | |
  • | 4. HEPATIC ENCEPHALOPATHY (HE) |
  • | - Precipitated by: Constipation, GI bleeding, infection, hypokalemia, |
  • | dehydration, psychoactive medications. |
  • | - First-Line Treatment: LACTULOSE (20-30 g oral TID-QID titrated to |
  • | achieve 2 to 3 soft bowel movements/day; traps NH4+ in stool). |
  • | - Second-Line / Adjunct: RIFAXIMIN (550 mg orally BID) added for |
  • | recurrent HE despite lactulose monotherapy. |
  • | |
  • | 5. HEPATOCELLULAR CARCINOMA (HCC) SURVEILLANCE |
  • | - Surveillance Protocol: ABDOMINAL ULTRASOUND +/- SERUM ALPHA- |
  • | FETOPROTEIN (AFP) EVERY 6 MONTHS for all patients with cirrhosis. |
  • +-----------------------------------------------------------------------------+
  • 5. Cholelithiasis, Acute Cholecystitis & Biliary Tract Emergencies

Gallstone disease (cholelithiasis) affects 10% to 15% of the adult population. Stones form primarily due to cholesterol supersaturation in bile, gallbladder hypomotility, or accelerated crystallization. Risk factors encompass the classic "5 F's" : Female, Forty, Fat (obesity), Fertile (multiparity/estrogen), and Family history . +-----------------------------------------------------------------------------+

  • | SPECTRUM OF BILIARY TRACT DISORDERS |
  • | |
  • | CONDITION PATHOLOGY CLINICAL SIGNS / LABS |
  • | ----------------------------------------------------------------------- |
  • | Biliary Colic Transient cystic duct Colicky RUQ pain lasting 1-5 hr|
  • | obstruction by stone Postprandial (fatty meals). |
  • | Normal labs, afebrile. |
  • | |
  • | Acute Cholecystitis Sustained cystic duct CONSTANT RUQ pain > 6 hrs, |
  • | obstruction -> mucosa fever, leukocytosis, POSITIVE |
  • | inflammation/infection MURPHY'S SIGN. |
  • | |
  • | Choledocholithiasis Stone in Common Bile RUQ pain, JAUNDICE, elevated |
  • | Duct (CBD) direct bilirubin, elevated Alk |
  • | Phos/GGT, dilated CBD on US. |
  • | |
  • | Acute Ascending Bacterial infection CHARCOT'S TRIAD: RUQ Pain + |
  • | Cholangitis of obstructed biliary Fever/Chills + Jaundice. |
  • | tree (E. coli, Klebs) REYNOLDS' PENTAD: Charcot's + |
  • | Hypotension + Mental Confusion |
  • | (SURGICAL / ERCP EMERGENCY!) |
  • +-----------------------------------------------------------------------------+
  • Diagnostic Evaluation & Physical Examination Signs

Murphy's Sign: Palpate the right upper quadrant below the costal margin and ask the patient to take a deep inspiration. A positive test is the sudden inspiratory arrest due to sharp pain when the inflamed gallbladder descends and contacts the examining fingers.

Imaging Modality of Choice: Right Upper Quadrant (RUQ) Abdominal Ultrasound (Sensitivity > 90% for stones).

Ultrasound Findings of Acute Cholecystitis: Gallbladder wall thickening (> 3 mm), pericholecystic fluid halo, gallstones with acoustic shadowing, and a sonographic Murphy's sign .

HIDA Scan (Cholescintigraphy): The most sensitive and specific diagnostic test for acute cholecystitis when ultrasound is equivocal. Non-visualization of the gallbladder after 1–4 hours indicates complete cystic duct obstruction.